Literature DB >> 33540821

MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.

Joshua R Huot1,2, Fabrizio Pin2, Alyson L Essex2, Andrea Bonetto1,2,3,4,5.   

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related death, and the prevalence of CRC in young adults is on the rise, making this a largescale clinical concern. Advanced CRC patients often present with liver metastases (LM) and an increased incidence of cachexia, i.e., musculoskeletal wasting. Despite its high incidence in CRC patients, cachexia remains an unresolved issue, and animal models for the study of CRC cachexia, in particular, metastatic CRC cachexia, remain limited; therefore, we aimed to establish a new model of metastatic CRC cachexia. C57BL/6 male mice (8 weeks old) were subcutaneously (MC38) or intrasplenically injected (mMC38) with MC38 murine CRC cells to disseminate LM, while experimental controls received saline (n = 5-8/group). The growth of subcutaneous MC38 tumors was accompanied by a reduction in skeletal muscle mass (-16%; quadriceps muscle), plantarflexion force (-22%) and extensor digitorum longus (EDL) contractility (-20%) compared to experimental controls. Meanwhile, the formation of MC38 LM (mMC38) led to heighted reductions in skeletal muscle mass (-30%; quadriceps), plantarflexion force (-28%) and EDL contractility (-35%) compared to sham-operated controls, suggesting exacerbated cachexia associated with LM. Moreover, both MC38 and mMC38 tumor hosts demonstrated a marked loss of bone indicated by reductions in trabecular (Tb.BV/TV: -49% in MC38, and -46% in mMC38) and cortical (C.BV/TV: -12% in MC38, and -8% in mMC38) bone. Cell culture experiments revealed that MC38 tumor-derived factors directly promote myotube wasting (-18%) and STAT3 phosphorylation (+5-fold), while the pharmacologic blockade of STAT3 signaling was sufficient to preserve myotube atrophy in the presence of MC38 cells (+21%). Overall, these results reinforce the notion that the formation of LM heightens cachexia in an experimental model of CRC.

Entities:  

Keywords:  bone; cachexia; colorectal cancer; liver metastases; skeletal muscle

Mesh:

Substances:

Year:  2021        PMID: 33540821      PMCID: PMC7867345          DOI: 10.3390/ijms22031486

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  35 in total

Review 1.  Guidelines for assessment of bone microstructure in rodents using micro-computed tomography.

Authors:  Mary L Bouxsein; Stephen K Boyd; Blaine A Christiansen; Robert E Guldberg; Karl J Jepsen; Ralph Müller
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

2.  An Epidemiological Survey of Cachexia in Advanced Cancer Patients and Analysis on Its Diagnostic and Treatment Status.

Authors:  Lei Sun; Xiao-Qing Quan; Shiying Yu
Journal:  Nutr Cancer       Date:  2015-08-28       Impact factor: 2.900

3.  An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice.

Authors:  Maria Rohm; Michaela Schäfer; Victor Laurent; Bilgen Ekim Üstünel; Katharina Niopek; Carolyn Algire; Oksana Hautzinger; Tjeerd P Sijmonsma; Annika Zota; Dasa Medrikova; Natalia S Pellegata; Mikael Ryden; Agné Kulyte; Ingrid Dahlman; Peter Arner; Natasa Petrovic; Barbara Cannon; Ez-Zoubir Amri; Bruce E Kemp; Gregory R Steinberg; Petra Janovska; Jan Kopecky; Christian Wolfrum; Matthias Blüher; Mauricio Berriel Diaz; Stephan Herzig
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

4.  Physiological characterization of a mouse model of cachexia in colorectal liver metastases.

Authors:  Kate T Murphy; Adam Struk; Cathy Malcontenti-Wilson; Christopher Christophi; Gordon S Lynch
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

Review 5.  Mechanisms of cancer cachexia.

Authors:  Michael J Tisdale
Journal:  Physiol Rev       Date:  2009-04       Impact factor: 37.312

6.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

7.  Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia.

Authors:  Michaela Schäfer; Christian U Oeing; Maria Rohm; Ezgi Baysal-Temel; Lorenz H Lehmann; Ralf Bauer; H Christian Volz; Michael Boutros; Daniela Sohn; Carsten Sticht; Norbert Gretz; Katrin Eichelbaum; Tessa Werner; Marc N Hirt; Thomas Eschenhagen; Karin Müller-Decker; Oliver Strobel; Thilo Hackert; Jeroen Krijgsveld; Hugo A Katus; Mauricio Berriel Diaz; Johannes Backs; Stephan Herzig
Journal:  Mol Metab       Date:  2015-11-26       Impact factor: 7.422

8.  Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways.

Authors:  Rafael Barreto; Giorgia Mandili; Frank A Witzmann; Francesco Novelli; Teresa A Zimmers; Andrea Bonetto
Journal:  Front Physiol       Date:  2016-10-19       Impact factor: 4.566

9.  Differential Bone Loss in Mouse Models of Colon Cancer Cachexia.

Authors:  Andrea Bonetto; Joshua K Kays; Valorie A Parker; Ryan R Matthews; Rafael Barreto; Melissa J Puppa; Kyung S Kang; James A Carson; Theresa A Guise; Khalid S Mohammad; Alexander G Robling; Marion E Couch; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Front Physiol       Date:  2017-01-11       Impact factor: 4.566

10.  ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.

Authors:  Rafael Barreto; Yukiko Kitase; Tsutomu Matsumoto; Fabrizio Pin; Kyra C Colston; Katherine E Couch; Thomas M O'Connell; Marion E Couch; Lynda F Bonewald; Andrea Bonetto
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

View more
  8 in total

1.  Cannabinoids orchestrate cross-talk between cancer cells and endothelial cells in colorectal cancer.

Authors:  Cong-Kai Luo; Pei-Hsuan Chou; Shang-Kok Ng; Wen-Yen Lin; Tzu-Tang Wei
Journal:  Cancer Gene Ther       Date:  2021-05-18       Impact factor: 5.987

Review 2.  Role of myokines and osteokines in cancer cachexia.

Authors:  Fabrizio Pin; Lynda F Bonewald; Andrea Bonetto
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-25

3.  GSI Treatment Preserves Protein Synthesis in C2C12 Myotubes.

Authors:  Joshua R Huot; Brian Thompson; Charlotte McMullen; Joseph S Marino; Susan T Arthur
Journal:  Cells       Date:  2021-07-15       Impact factor: 7.666

4.  Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) R47H Variant Causes Distinct Age- and Sex-Dependent Musculoskeletal Alterations in Mice.

Authors:  Alyson L Essex; Joshua R Huot; Padmini Deosthale; Alison Wagner; Jorge Figueras; Azaria Davis; John Damrath; Fabrizio Pin; Joseph Wallace; Andrea Bonetto; Lilian I Plotkin
Journal:  J Bone Miner Res       Date:  2022-06-07       Impact factor: 6.390

5.  miR21 deletion in osteocytes has direct and indirect effects on skeletal muscle in a sex-dimorphic manner in mice.

Authors:  Alyson L Essex; Padmini Deosthale; Joshua R Huot; Hannah M Davis; Nicholas Momeni; Andrea Bonetto; Lilian I Plotkin
Journal:  Biol Sex Differ       Date:  2022-10-01       Impact factor: 8.811

Review 6.  Muscle and Bone Defects in Metastatic Disease.

Authors:  Martina Pauk; Hiroaki Saito; Eric Hesse; Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2022-08-22       Impact factor: 5.163

7.  Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity.

Authors:  Joshua R Huot; Fabrizio Pin; Andrea Bonetto
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  Non-bone metastatic cancers promote osteocyte-induced bone destruction.

Authors:  Fabrizio Pin; Matthew Prideaux; Joshua R Huot; Alyson L Essex; Lilian I Plotkin; Andrea Bonetto; Lynda F Bonewald
Journal:  Cancer Lett       Date:  2021-07-04       Impact factor: 9.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.